To Label or Not to Label - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

To Label or Not to Label
In light of compendial changes, representatives of the US Pharmacopeia and an industry consortium provide perspectives on cap and ferrule labels.


Pharmaceutical Technology
Volume 10, Issue 34, pp. 96-98

Implementation

According to FDA, if manufacturers believe they need to include a cautionary statement about an imminent life-threatening situation on the ferrule or cap overseal of their product, they must provide a rationale to FDA regarding why the situation addressed in the statement is considered to be life-threatening. FDA will expect manufacturers to provide data to support the assertion that the statement is safe, unambiguous, and provides the best message to minimize the life-threatening situation. Given the effects this change could have on manufacturers, the USP Nomenclature Expert Committee established a delayed official date for the revised standard. The standard will be published formally on Nov. 1, 2010, in USP 34–NF 29 and will become official Dec. 1, 2013, thereby giving industry three years to implement the change.

USP appreciates the input of all parties regarding this revised standard, and recognizes the changes the standard will require of manufacturers in the coming years. USP believes this activity will support healthcare professionals in their work and help protect patients from serious medication errors that could result in death and disability.

Reference

1. USP, Commentary–General Chapter <1>, Aug. 4, 2010, http://www.usp.org/pdf/EN/USPNF/genChapter1Commentary.pdf, accessed Aug. 31, 2010.

2. IOM, To Err is Human: Building a Safer Health System (National Academy Press, Washington, DC, 2000).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here